were maintained in alpha-MEM, RPMI1640 or DMEM, respectively, and were subcultured for ≤20 dissolved in DMSO and diluted 1:500 or 1:1,000 in media before use. Cells were usually treated with racemic C75 except one experiment, in which racemic C75 was compared with the enantiomers.
Introduction
For the last thirty years cancer researchers paid most attention to the discovery of genetic alterations in oncogenic and tumor suppressor genes, which function as regulators of growth, migration and apoptosis. 1 This led to the identification of cancer drug targets and corresponding therapeutics, which are added to the armamentarium in the fight against cancer. In the case of ovarian cancer (OC), however, this approach has yielded only limited benefits. 2 Thus, especially for advanced OC, novel approaches are urgently needed. Notably, it has been known for decades that cancer cells reveal alterations in their metabolism such as aerobic glycolysis, acidosis, glutamine consumption and hypoxia. 3, 4 Recently, it has been recognized that metabolic pathways closely interact with oncogenic networks and that altered oncogenes and tumor suppressor genes directly affect cancer cell metabolism. 5 For instance, the proto-oncogene c-Myc crosstalks with hypoxia-inducible factors enabling continued proliferation despite tissue hypoxia 6 and spurs aerobic glycolysis and acidosis. 7 Cancer cells not only have high demands for bioenergy for cell division provided by catabolic pathways, they also depend on supply with biomolecules for building new cell material. Both requirements are met by glycolytic breakdown of carbohydrates, which not only provide moderate levels of ATP, but also deliver components for biosynthesis of macromolecules. 8 In addition, cancer cells have been found to reveal hyperactivation of de novo (phospho)lipid synthesis, which is required for production of biomembranes. 9 Thus, fatty acid synthase (FASN), the key enzyme for production of palmitic acid, which is the precursor of all lipids, 10 is overexpressed in cancer cells, confers chemoresistance and correlates with tumor progression. [11] [12] [13] In contrast, most normal cells (except hepatocytes, adipocytes) are essentially negative for FASN. 9 Interestingly, data from metabolic radiolabeling indicate that senescent cells, unlike proliferating cells, reveal reduced de novo synthesis of phospholipids (PLs), but elevated levels of cholesterol and of unsaturated fatty acids 14 suggesting changes of lipid metabolism. Notably, high levels of EGFR-, HER2-or AKToncoprotein correlate with FASN overexpression/phosphorylation corroborating the link between F o r P e e r R e v i e w 6 oncogene pathways and metabolic systems. [15] [16] [17] Most importantly, blunting FASN-action arrests growth and induces death in cancer cells prompting the development of FASN-inhibitory compounds for cancer treatment. 18 Thus, FASN represents a cancer biomarker and a promising target. It is therefore tempting to speculate that FASN-targeting will represent a novel anti-metabolic approach to be added to the armamentarium against OC.
In contrast to the widely accepted concept that normal cells are negative for FASN and insensitive against FASN-blockers, we report here that normal non-malignant human ovarian surface epithelial cells and oviduct secretory epithelial cells, from which high-grade serous OCs arise, do produce high amounts of FASN and depend on it for growth in culture. However, during ageing in culture, they downregulate FASN and lose responsiveness to FASN-inhibitors. Correspondingly, in the body, healthy epithelia from the ovarian surface and from the fimbriae of the oviduct were quiescent and FASN-negative, whereas cancer tissues expressed FASN according to their growth activity. Using
FASN-targeting drugs we demonstrate that FASN-inhibition impairs cancer cells causing cell cycle
block and apoptosis in vitro, whereas in healthy proliferating cells they only reduce cell cycle progression. Moreover, characteristic differences in the lipid profiles of non-malignant young and senescent cells and after FASN-inhibition in young cells were observed. In summary, our data demonstrate that FASN is associated with cell proliferation rather than with malignancy and that FASN is a useful cancer target since quiescent normal cells usually lack it and the few dividing normal cells, being positive for it, are not eliminated by the FASN-drugs.
Materials and Methods
Cell Culture and Drugs were maintained in alpha-MEM, RPMI1640 or DMEM, respectively, and were subcultured for ≤20 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In-situ Staining for Senescence-Associated-β-Galactosidase (SA-β-gal) However, only the (-)-form interferes with FASN-activity. 22 Consequently, (-)-C75 inhibits growth at least as efficiently as the mixture, whereas (+)-C75 lacks efficacy ( Figure 1c ). This data together with the inefficiency of racemic C75 and G28UCM on fibroblasts suggests that non-malignant ovarian/oviductal cells are not inhibited due to off-target drug effects.
Inhibition of FASN in OC causes conversion of membrane-phospholipids (PLs) into storage-lipids
Conceivably, inhibitors of FASN activity not only block cell growth, but also severely affect cell lipid were detected. The relative distribution of these classes was different between both cell lines; DAG, PE, PC were equally abundant in SKOV3, whereas in OVCAR-3 PC was predominant, PE was as 
Senescent cultures of ovarian cells are negative for FASN and resistant to FASN inhibitors
Primary OSE show spontaneous senescence in vitro. Therefore, we wondered whether FASNexpression and FASN-drug sensitivity ceases in these cells after prolonged culture. As shown in Figure   3a , OSE cells cultivated for 22d downregulate FASN while upregulating expression of β-galactosidase 
Downregulation of FASN is dependent on growth arrest but not on cell senescence
For many years the human OSE has been considered to represent the genuine tissue of origin for high-grade serous OCs, which constitute 60-80% of all human epithelial OCs. During the last decade, however, ample evidence challenged this concept and caused a change of paradigm. Accordingly, data suggest that both the ovarian surface epithelium and the secretory epithelium of the fallopian Next, we wondered whether FASN-expression and FASN-drug sensitivity are regulated in a similar manner in transformed OC cells. To this end, we took advantage of an OC cell subline system that we have previously established. Using density-gradient-centrifugation of the polyclonal parental cell line HOC-7 (P) we isolated three monoclonal sublines from the high-density fractions of the gradient (N1-N3) and three others from the low-density gradient-fractions (D1-D3). HOC-7 parental P-cells and Nsubclones grow significantly faster than the D-subclones (Figure 5a) . Overall, the D-phenotype reflects a more differentiated functional state. 19, 38 Notably, D-cells express lower levels of FASNprotein than P-and N-cells and are less sensitive to FASN-inhibitors than P-and N-cells (Figures 5b,c) .
Interestingly, when P-or N-cells are exposed to differentiation inducers like DMSO, they cease growth ( Figure 5d ) and adopt a differentiated state, which is identical to the spontaneous Dphenotype. Thus, differentiation-inducing chemicals indeed stimulate an endogenous cell maturation process rather than just eliciting toxic stress. 27,28 Ultimately, DMSO-differentiated HOC-7 P-cells become senescent as evidenced by the expression of SA-β-gal, downregulate FASN-protein and become resistant against inhibition of lipogenesis (Figures 5e,f) . Figure 3 ).
FASN-inhibitors do not block the cell cycle and do not induce apoptosis in normal ovarian cells
Remarkably, elevating FASN-protein levels in these senescent IOSE cells by introducing wild-type FASN-transgene is sufficient to reactivate DNA-synthesis and cell proliferation. We also used fallopian tube secretory epithelial cells of the oviduct, which were fully immortalized by eliminating the p53/pRB-pathway using either SV40T/t or a p53 shRNA together with mutant CDK4 and by introduction of hTERT, the catalytic subunit of telomerase that prevents telomere shortening and abrogates replicative senescence yielding immortal but non-tumorigenic FT33-TAg and FT237-shp cell lines. 20 Nonetheless, these cells yet reveal differences in their proliferative activity and were thus useful to address the question whether FASN-target expression and sensitivity against FASNinhibitors are dependent on the senescence process per se or are only related to cell proliferation. 
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Supplementary Information Supplementary Materials and Methods
In Situ Staining for Senescence-Associated β-Galactosidase (SA-β-gal)
SA-β-gal with a pH optimum of 6.0 is a marker for cellular senescence. This senescence-associated form of β-galactosidase has recently been shown to be of lysosomal origin. S1 Here we used a β-galactosidase staining kit from Abnova (Taipei, Taiwan) for detection of this cell ageing marker. IOSE-80 cells at different stages of senescence (after 15 and 24 passages, corresponding to 10 and 58d in continuous culture) were plated in 24 well plates (0.4 and 1.2x10 4 /well) and were grown for 72hr before being washed in buffer, fixed and stained overnight at 37°C in a humidified chamber under atmospheric CO 2 using freshly prepared staining buffer. The procedure was performed according to the manufacturer's (Abnova) protocol except that pH was lowered from 7.2 to 6.0 for staining. Cells were then washed and examined under the microscope at ×40 and x100 magnifications. 
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